| Literature DB >> 35193565 |
Yuan Li1, Zhi-Gang Yang2, Jin Wang3, Ying-Kun Guo4, Shan Huang3, Rui Shi3, Wei-Feng Yan3, Wen-Lei Qian3, Guang-Xi He3.
Abstract
BACKGROUND: Coronary artery disease (CAD) confers considerable morbidity and mortality in diabetes. However, the role of CAD in additive effect of left ventricular (LV) function has rarely been explored in type 2 diabetes mellitus (T2DM) patients. This study aimed to investigate how CAD affect LV systolic and diastolic function in T2DM patients.Entities:
Keywords: Coronary artery disease; Left ventricular; Magnetic resonance imaging; Strain; Type 2 diabetes mellitus
Mesh:
Substances:
Year: 2022 PMID: 35193565 PMCID: PMC8864799 DOI: 10.1186/s12933-022-01467-y
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Baseline characteristics of the study population
| Normal controls | T2DM | ||
|---|---|---|---|
| (n = 83) | T2DM (CAD | T2DM (CAD | |
| Age (years) | 56.45 ± 10.05 | 57.33 ± 12.12 | 61.86 ± 9.83*§ |
| Male, n (%) | 55(66.3%) | 101(56.7%) | 82 (78.8%) § |
| BMI (kg/m2) | 21.24 ± 3.44 | 22.58 ± 9.58 | 25.47 ± 4.34*§ |
| BSA (m2) | 1.58 ± 0.15 | 1.52 ± 0.57 | 1.76 ± 0.19*§ |
| Smoking, n (%) | 8(9.6%) | 62(34.8%) * | 52(51.5%) *§ |
| Systolic blood pressure (mmHg) | 111.66 ± 10.54 | 134.21 ± 21.12* | 131.59 ± 22.01* |
| Diastolic blood pressure (mmHg) | 74.17 ± 6.11 | 82.05 ± 14.12* | 80.43 ± 14.43* |
| Heart rate (beats/min) | 71.93 ± 5.67 | 83.81 ± 15.32* | 80.28 ± 13.84* |
| Fasting blood glucose (mmol/L) | 4.9 (4.5, 5.1) | 7.2 (5.7, 9.3) * | 8.9 (6.7, 13.2) *§ |
| HbA1c, (%) | 5.1 (4.9, 5.4) | 6.8 (6.4, 7.4) * | 7.9 (7.3, 8.6) *§ |
| TG (mmol/L) | 1.0 (0.7, 1.3) | 1.5 (1.0, 2.1) * | 1.4 (1.0, 2.2) * |
| TC (mmol/L) | 3.8 (3.1, 4.5) | 4.0 (3.2, 4.7) | 3.8 (3.1, 4.6) |
| HDL (mmol/L) | 1.2 (1.1, 1.5) | 1.1 (0.9, 1.4) * | 1.0 (0.9, 1.2) * |
| LDL (mmol/L) | 2.1 (1.6, 2.8) | 2.1 (1.6, 2.7) | 2.0 (1.5, 2.7) |
| eGFR (mL/min/1.73 m2) | 91.6 (81, 99.9) | 80.0 (62.2, 96.2) * | 79.1 (67.2, 92.3) * |
| NT-proBNP, (pg/mL) | 51 (29,60) | 394 (131,1494) * | 509 (208, 2020) *§ |
| Diabetes duration (years) | – | 2 (0, 7.5) | 4.5 (0.63, 10) § |
| Gensini score | – | – | 60 (39, 97) |
| Number of coronary arteries affected | |||
| One/Two/Three-vessel | – | – | 34/30/40 |
| Location of coronary artery occlusion | |||
| (LAD/LCX/RCA) | – | – | 95/52/66 |
All values are presented as mean ± SD or n (%) or median (Q1-Q3)
T2DM type 2 diabetes mellitus, CAD coronary artery disease, BSA body surface area, BMI body mass index, HbA1c glycated haemoglobin, TG triglycerides, TC total cholesterol, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate, NT-proBNP N-terminal pro-brain natriuretic peptide, LAD left descending artery, LCX left circumflex artery, RCA right coronary artery
*P < 0.017 vs. normal controls; §P < 0.017 vs. T2DM (CAD −) group
Treatment in patients with T2DM
| T2DM (CAD | T2DM (CAD +) (n = 104) | ||
|---|---|---|---|
| Diabetic treatment | |||
| Biguanides, n (%) | 59 (33.1%) | 43 (41.4%) | 0.167 |
| Sulfonylureas, n (%) | 31 (17.4%) | 18 (17.3%) | 0.982 |
| a-Glucosidase inhibitor, n (%) | 48 (27%) | 31 (29.8%) | 0.608 |
| GLP-1/DPP-4 inhibitor, n (%) | 9 (5%) | 5 (4.8%) | 0.926 |
| Insulin, n (%) | 46 (25.8%) | 38 (36.5%) | 0.058 |
| Diet controlled | 60 (33.7%) | 22 (21.2%) | 0.025 |
| CAD treatment | |||
| Drugs | |||
| Aspirin, n (%) | – | 83 (79.8%) | – |
| Clopidogrel, n (%) | – | 73 (70.2%) | – |
| Warfarin, n (%) | – | 3 (2.9%) | – |
| Statins, n (%) | – | 89 (85.6%) | – |
| Beta blockers, n (%) | – | 44 (42.3%) | – |
| ACEI, ARB, n (%) | – | 40 (38.5%) | – |
| Nitrate, n (%) | – | 8 (7.7%) | – |
| Trimetazidine hydrochloride, n (%) | – | 14 (13.5%) | – |
| Calcium antagonists, n (%) | – | 26 (25%) | – |
| PCI | – | 64 (61.5%) | – |
| CABG | – | 3 (2.9%) | – |
All values are presented as n (%). GLP-1/DPP-4 inhibitor glucagon-like peptide-1/dipeptidyl peptidase 4 inhibitors, PCI percutaneous coronary intervention, CABG coronary artery bypass grafting, ACEI angiotensin converting enzyme inhibitor
Comparison of CMR-derived parameters among normal controls, T2DM patients with and without CAD
| Normal controls | T2DM | |||
|---|---|---|---|---|
| (n = 83) | T2DM (CAD | T2DM (CAD | ||
| LV geometry and function | ||||
| LVEDVI (mL/m2) | 79.0 (67.0, 87.7) | 89.3 (74.6, 117.5)* | 106.5 (79.0, 141.4)*§ | |
| LVESVI (mL/m2) | 28.0 (23.9, 33.1) | 37.5 (26.9, 72.9)* | 59.2 (36.1, 107.8)*§ | |
| LVSVI (mL/m2) | 49.8 (42.3, 54.4) | 46.7 (35.5, 55.5) | 40.1 (32.0, 48.6)*§ | |
| LVEF (%) | 63.1 (58.0, 67.8) | 55.1 (40.5, 63.5)* | 37.2 (27.0, 52.4)*§ | |
| LVMI (g/m2) | 42.0 (35.4, 47.5) | 51.5 (43.1, 68.4)* | 59.3 (50.1, 66.6)* | |
| PS (%) | ||||
| GRPS | 35.3 (30.4, 38.8) | 24.2 (13.4, 33.6) * | 18.1 (9.5, 23.9) *§ | |
| GCPS | − 20.8 (− 22.2, − 19.1) | − 16.9 (− 20.7, − 10.6) * | − 12.2 (− 16.3, − 7.5) *§ | |
| GLPS | − 14.4 (− 16.7, − 12.2) | − 10.0 (− 12.5, − 5.9) * | − 7.8 (− 10.0, − 5.2) *§ | |
| PSSR (1/s) | ||||
| Radial | 2.0 (1.7, 2.4) | 1.4 (0.7, 1.9)* | 1.0 (0.6, 1.5)*§ | |
| Circumferential | − 1.0 (− 1.2, − 0.9) | − 0.9 (− 1.1, − 0.6)* | − 0.7 (− 0.8, − 0.5)*§ | |
| Longitudinal | − 0.8 (− 0.9, − 0.6) | − 0.7 (− 0.8, − 0.4)* | − 0.5 (− 0.7, − 0.4)*§ | |
| PDSR (1/s) | ||||
| Radial | − 1.1 (− 1.5, − 0.6) *§ | |||
| Circumferential | 1.3 (1.1, 1.5) | 0.9 (0.6, 1.1)* | 0.7 (0.5, 0.9)*§ | |
| Longitudinal | 0.9 (0.7, 1.1) | 0.6 (0.5, 0.8)* | 0.6 (0.4, 0.7) * | |
| LGE | ||||
| LGE, n (%) | – | 56 (31.5%) | 104 (100%) § | |
| LGE rel (%) | – | 7.7 (4.1, 16.8) % | 22.6 (12.9, 46.3)% § | |
All values are presented as n (%) or median (Q1-Q3). “−” indicates the direction of strains. LV left ventricular, EF ejection fraction, EDV end-diastolic volume, ESV end-systolic volume, SV stroke-volume, I indexed to BSA, PS peak strain, GRPS global radial peak strain, GCPS global circumferential peak strain, GLPS global longitudinal peak strain, PSSR peak systolic strain rate, PDSR peak diastolic strain rate, LGE late gadolinium enhancement
*P < 0.017 vs. normal group; §P < 0.017 vs. T2DM (CAD-) group
Fig. 1Representative CMR pseudo-color images at the end-systole and global PS curves in a normal control, T2DM (CAD −) patient, and T2DM (CAD +) patient. A1–C1 pseudo-color images of LV radial PS in short-axis; A3–C3 three-dimensional pseudo-color maps of LV circumferential PS; A5, B5, C5 pseudo-color images of LV longitudinal PS in four-chamber long-axis; A2–C2 LV global PS curve in radial direction; A4, B4, C4 LV global PS curve in circumferential direction; A6, B6, C6 LV global PS curve in longitudinal direction. CMR cardiac magnetic resonance, PS peak strain, LV left ventricle, T2DM type 2 diabetes mellitus, CAD coronary artery disease
Fig. 2Comparison of LV global strains among T2DM (CAD +) patients with different Gensini score and normal controls. The absolute values of LV global strains were used to avoid the influence of directional sign. PS peak strain, GRPS global radial peak strain, GCPS global circumferential peak strain, GLPS global longitudinal peak strain, PSSR peak systolic strain rate, PDSR peak diastolic strain rate, R radial, C circumferential, L longitudinal, T2DM type 2 diabetes mellitus, CAD coronary artery disease. *P < 0.017
Effect of CAD on the LV systolic and diastolic function in T2DM patients
| GRPS (%) | GLPS (%) | GCPS (%) | PSSR-C (1/s) | PDSR-C (1/s) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | |
| r | β | r | β | r | β | r | β | r | β | |
| CAD | 0.23§ | 0.19* | 0.21§ | 0.18* | 0.28§ | 0.22* | 0.27§ | 0.17* | 0.27§ | 0.22* |
| Sex | N/A | −0.22* | ||||||||
| Age | N/A | N/A | N/A | N/A | N/A | |||||
| BMI | N/A | N/A | N/A | 0.01 | N/A | − 0.06 | N/A | |||
| BSA | N/A | N/A | N/A | N/A | N/A | |||||
| SBP | 0.17§ | N/A | 0.10§ | N/A | 0.20§ | 0.17* | 0.17§ | 0.13* | 0.11§ | N/A |
| DBP | 0.01 | N/A | N/A | 0.03 | N/A | 0.05 | N/A | 0.05 | N/A | |
| Heart rate | N/A | N/A | ||||||||
| Smoking | N/A | N/A | N/A | N/A | N/A | |||||
| Diabetes duration | N/A | N/A | N/A | N/A | N/A | |||||
β is adjusted regression coefficient
Factors with P < 0.1 in the univariable analyses were included in the stepwise multiple liner regression model
§P < 0.1
*P < 0.05
Abbreviations as in Tables 1, 3
Fig. 3The associations of LV global circumferential strains with Gensini score and LGE in T2DM (CAD +) patients. The absolute values of LV circumferential global peak strains were used to avoid the influence of directional sign. GCPS global circumferential peak strain, PSSR-C the global circumferential peak systolic strain rate, PDSR-C the global circumferential peak diastolic strain rate, T2DM type 2 diabetes mellitus, CAD coronary artery disease. *P < 0.001
Determinants of impaired LV systolic and diastolic function in T2DM(CAD +) patients
| GRPS (%) | GLPS (%) | GCPS (%) | PSSR-C (1/s) | PDSR-C (1/s) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | Univariable | Multivariable | |
| r | β | r | β | r | β | r | β | r | β | |
| Sex | N/A | N/A | N/A | N/A | ||||||
| Age | 0.18§ | N/A | 0.15 | N/A | 0.21§ | N/A | 0.14 | N/A | 0.10 | N/A |
| Smoking | N/A | N/A | N/A | |||||||
| BMI | 0.10 | N/A | 0.06 | N/A | 0.04 | N/A | 0.10 | N/A | 0.10 | N/A |
| BSA | N/A | N/A | N/A | 0.12 | N/A | N/A | ||||
| Heart rate | N/A | N/A | N/A | |||||||
| SBP | 0.32§ | N/A | 0.28 | N/A | 0.33§ | N/A | 0.32§ | N/A | 0.26§ | N/A |
| DBP | 0.10 | N/A | 0.07 | N/A | 0.11 | N/A | 0.12 | N/A | 0.13 | N/A |
| Nt-proBNP# | ||||||||||
| Diabetes duration | 0.14 | N/A | 0.15 | N/A | 0.15 | N/A | 0.03 | N/A | 0.01 | N/A |
| HbA1c | N/A | N/A | N/A | N/A | N/A | |||||
| Gensini score | ||||||||||
| LGE rel | ||||||||||
β is adjusted regression coefficient
#NT-proBNP is log-transformed before being included in the regression model
Factors with P < 0.1 in the univariable analyses were included in the stepwise multiple liner regression model
§P < 0.1
*P < 0.05
Abbreviations as in Tables 1, 3
Inter-and intra-observer variabilities of LV myocardial strain
| Inter-observer (n = 40) | Intra-observer (n = 40) | |||
|---|---|---|---|---|
| ICC | 95% CI | ICC | 95% CI | |
| PS (%) | ||||
| GRPS | 0.932 | 0.859–0.966 | 0.969 | 0.943–0.984 |
| GCPS | 0.960 | 0.926–0.979 | 0.951 | 0.900–0.975 |
| GLPS | 0.905 | 0.829–0.949 | 0.900 | 0.820–0.946 |
| PSSR (1/s) | ||||
| Radial | 0.893 | 0.803–0.943 | 0.925 | 0.863–0.959 |
| Circumferential | 0.909 | 0.836–0.951 | 0.939 | 0.888–0.967 |
| Longitudinal | 0.896 | 0.812–0.944 | 0.901 | 0.822–0.947 |
| PDSR (1/s) | ||||
| Radial | 0.944 | 0.882–0.972 | 0.951 | 0.909–0.974 |
| Circumferential | 0.902 | 0.823–0.947 | 0.932 | 0.875–0.963 |
| Longitudinal | 0.895 | 0.804–0.944 | 0.908 | 0.834–0.950 |
ICC intraclass correlation coefficient, CI confidence interval, PS peak strain, GRPS global radial peak strain, GCPS global circumferential peak strain, GLPS global longitudinal peak strain, PSSR peak systolic strain rate, PDSR peak diastolic strain rate